New England Journal of Medicine· 2020Q1· Clinical trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff et al.

10,782citations
Q1SCImago
2020year

Short summary

The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 illness, including severe disease, in a large-scale Phase 3 trial.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Infectious Diseases

Infectious DiseasesMedicine